Literature DB >> 30178096

[Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)].

D Müller-Wieland1, S Nitschmann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30178096     DOI： 10.1007/s00108-018-0486-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  5 in total

1.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

2.  Uric acid is predictive of cardiovascular mortality and sudden cardiac death in subjects referred for coronary angiography.

Authors:  G Silbernagel; M M Hoffmann; T B Grammer; B O Boehm; W März
Journal:  Nutr Metab Cardiovasc Dis       Date:  2011-06-23       Impact factor: 4.222

3.  Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.

Authors:  Su-Mi Kim; Sang-Ho Lee; Yang-Gyun Kim; Se-Yun Kim; Jung-Woo Seo; Young-Wook Choi; Dong-Jin Kim; Kyung-Hwan Jeong; Tae-Won Lee; Chun-Gyoo Ihm; Kyu-Yeoun Won; Ju-Young Moon
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-28

Review 4.  Uric acid in metabolic syndrome: From an innocent bystander to a central player.

Authors:  Mehmet Kanbay; Thomas Jensen; Yalcin Solak; Myphuong Le; Carlos Roncal-Jimenez; Chris Rivard; Miguel A Lanaspa; Takahiko Nakagawa; Richard J Johnson
Journal:  Eur J Intern Med       Date:  2015-12-15       Impact factor: 4.487

Review 5.  Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Markus Bredemeier; Lediane Moreira Lopes; Matheus Augusto Eisenreich; Sheila Hickmann; Guilherme Kopik Bongiorno; Rui d'Avila; André Luis Bittencourt Morsch; Fernando da Silva Stein; Guilherme Gomes Dias Campos
Journal:  BMC Cardiovasc Disord       Date:  2018-02-07       Impact factor: 2.298
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.